Vectura Group PLC’s (VEC) Buy Rating Reaffirmed at Numis Securities Ltd

Numis Securities Ltd reiterated their buy rating on shares of Vectura Group PLC (LON:VEC) in a report released on Friday. The firm currently has a GBX 225 ($2.78) price target on the stock.

VEC has been the topic of a number of other reports. JPMorgan Chase & Co. restated an overweight rating on shares of Vectura Group PLC in a research note on Tuesday, January 17th. Peel Hunt restated a buy rating and issued a GBX 200 ($2.47) price objective on shares of Vectura Group PLC in a research note on Wednesday, January 25th. Stifel Nicolaus restated a buy rating and issued a GBX 225 ($2.78) price objective on shares of Vectura Group PLC in a research note on Tuesday, January 24th. FinnCap restated a buy rating and issued a GBX 225 ($2.78) price objective on shares of Vectura Group PLC in a research note on Tuesday, November 29th. Finally, N+1 Singer restated a buy rating and issued a GBX 202 ($2.49) price objective on shares of Vectura Group PLC in a research note on Wednesday, January 11th. Seven equities research analysts have rated the stock with a buy rating, Vectura Group PLC presently has a consensus rating of Buy and an average price target of GBX 220.29 ($2.72).

Analyst Recommendations for Vectura Group PLC (LON:VEC)

Vectura Group PLC (LON:VEC) traded up 2.54% during mid-day trading on Friday, reaching GBX 157.40. 3,025,515 shares of the company’s stock were exchanged. The firm’s 50-day moving average is GBX 143.02 and its 200 day moving average is GBX 139.59. Vectura Group PLC has a 1-year low of GBX 122.90 and a 1-year high of GBX 179.00. The stock’s market capitalization is GBX 904.58 million.

Your IP Address:

About Vectura Group PLC

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply